1 active not recruiting, 1 unknown. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 1, Unknown 1 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Active not recruiting | Zhengzhou University | 34 | 2023-10-21 | 2025-07-01 |
| CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Unknown | Ruijin Hospital | 200 | 2012-09-01 | 2017-11-14 |
Enteropathy-Associated T-Cell Lymphoma (1) · Subcutaneous panniculitis-like T-cell lymphoma (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphadenopathy (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Azacitidine (1) · Cyclophosphamide (1) · Dasatinib (1) · Doxorubicin (1) · Etoposide (1) · Ifosfamide (1) · Methotrexate (1) · Prednisone (1) · Vincristine (1) · etoposide phosphate (1) · pirarubicin (1) · prednylidene (1)
Ruijin Hospital (1) · Zhengzhou University (1)
China (2)